← boardnext 2026-12
EPRX
Eupraxia Pharmaceuticals Inc.distress 2/10 · well-funded / low risk$6.36-1%today-30% from 52w high
Lead: Eosinophilic Esophagitis
Revenue
pre-revenue
Liquidity
$81M
Runway
2.8 yrs
Shares 1y
+31%
Price & events
-29.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
+3.2%
1W
-0.5%
1M
-12.3%
3M
-29.3%
6M
+25.7%
1Y
+145.1%
2Y
—
5Y
+115.6%
All
Overview
- Market Cap
- $226.68M
- Volume
- 5.14K
- 52 Week Range
- $5.05 – $9.07
- Total Shares
- 35.64M
- Float Shares
- 51.25M
- % Held by Insiders
- 14.22%
- % Held by Institutions
- 41.96%
- RVOL
- 0.01x
- Beta
- 1.50
Pipeline stages · 1 programs
EP-104GI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 1/2 | EP-104GI | Eosinophilic Esophagitis | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+156% upside) · 9 analysts
- 2026-06-26OppenheimerOutperform
- 2026-05-21StifelBuy
- 2026-05-04HC Wainwright & Co.Buy
- 2026-04-22HC Wainwright & Co.Buy
- 2026-03-23William BlairOutperform
- 2026-03-17HC Wainwright & Co.Buy
Competitors — Eosinophilic Esophagitis
Recent news
- 2026-07-22Eupraxia Pharmaceuticals (EPRX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-22Eupraxia Pharmaceuticals (EPRX) Bloom Burton & Co. Healthcare Investor Conference 2026 summary - Quartr
- 2026-07-21What's Going On With Eupraxia Pharmaceuticals Inc Stock Tuesday? - Wealth Awesome
- 2026-07-20Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
- 2026-07-17Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
- 2026-07-17Insider Stock Buying Reaches US$5.58m On Eupraxia Pharmaceuticals - simplywall.st
- 2026-07-16Why Eupraxia Pharmaceuticals Inc stock is plummeting today - Wealth Awesome
- 2026-07-15Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.